Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure

Purpose: IL-12 gene therapy is attractive for cancer because local IL-12 expression can prime anti-tumor immunity while reducing systemic toxicity. However, non-viral gene delivery to tumors is inefficient, and simple sonoporation using ultrasound alone does not achieve sufficient cancer gene therapy. The authors tested whether ultrasound-sensitive “Bubble liposomes” plus tumoral ultrasound could serve as an effective non-viral vector for IL-12 gene delivery.

Hypothesis: If IL-12-encoding plasmid DNA is delivered intratumorally using Bubble liposomes combined with ultrasound exposure, then IL-12 expression in the tumor will be enhanced and tumor growth will be suppressed through a T-cell-dependent anti-tumor immune response.

Aims: Evaluate gene delivery efficiency into solid OV-HM tumors using Bubble liposomes + ultrasound versus conventional Lipofectamine 2000. - Assess intratumoral IL-12 expression after pCMV-IL12 delivery with Bubble liposomes + ultrasound. - Determine the anti-tumor effect of single and repetitive IL-12 gene therapy. - Identify the immune cell subsets responsible for the therapeutic effect, focusing on CD4+, CD8+ T cells, and NK cells.

Delivery system: Platform: Bubble liposomes — ultrasound-sensitive liposomal nanobubbles. - Lipid composition: DSPC and DSPE-PEG(2k)-OMe at 94:6 (m/m). - Preparation: Reverse-phase evaporation; sized to 150–200 nm; supercharged with perfluoropropane gas and sonicated to form Bubble liposomes (~500 nm–1 µm). - Payload: Plasmid DNA encoding murine IL-12 under a CMV promoter (pCMV-IL12); pCMV-Luc used as reporter control. - Trigger: Transdermal ultrasound, 1 MHz, 0.7 W/cm², 60 s. - Targeting ligand: None. - Comparison: Lipofectamine 2000 as conventional lipofection.

Approach: Cell line/model: Murine ovarian carcinoma OV-HM cells. - In vivo model: B6C3F1 female mice, intradermal flank inoculation of 1 × 10⁶ OV-HM cells. - Treatment timing: Tumors treated 7 days after inoculation; established tumors 8–10 mm for therapy. - Dosing: Intratumoral injection of 25 µL containing Bubble liposomes (2.5 µg) + pCMV-IL12 or pCMV-Luc (10 µg), followed by ultrasound. - Controls: pCMV-IL12 alone, Bubble liposomes alone, ultrasound alone, Lipofectamine 2000 + pCMV-IL12, pCMV-Luc + Bubble liposomes + ultrasound. - Group size: Five mice per treatment group; luciferase expression assay used n = 3. - Repetitive therapy: Treatments on days 0, 2, 5, 7, 9, and 12. - Depletion assay: Anti-CD4, anti-CD8, or anti-asialoGM1 antibodies to deplete T-cell subsets or NK cells.

Key methods: Luciferase reporter assay for gene delivery efficiency. - RT-PCR for IL-12p40 mRNA expression in tumor tissue. - Tumor volume measurement for anti-tumor effect. - In vivo antibody depletion and flow cytometry for immune subset analysis. - Immunohistochemical staining for CD8+ T cells and perforin.

Key results: Reporter gene expression: Bubble liposomes + ultrasound produced significantly higher luciferase activity than plasmid alone, Bubble liposomes alone, ultrasound alone, or Lipofectamine 2000 (P < 0.01). Expression declined with elimination rate constant Ke = 1.26 days⁻¹ and half-life T₁/₂ = 0.54 days. - IL-12 expression: pCMV-IL12 alone showed no IL-12p40 mRNA. Lipofectamine 2000 gave only a small amount on day 1. Bubble liposomes + ultrasound produced detectable IL-12p40 mRNA for at least 2 days after transfection. - Anti-tumor effect: Single therapy suppressed tumor growth but did not cause complete regression. Repetitive therapy with pCMV-IL12 + Bubble liposomes + ultrasound caused complete regression in 80% of tumor-bearing mice and prolonged survival, with no body-weight decrease reported. - Immune mechanism: Anti-tumor effect was attenuated by CD4+ depletion and effectively blocked by CD8+ depletion; combined CD4+/CD8+ depletion also blocked the effect. NK depletion had no effect. Tumors treated with IL-12 + Bubble liposomes + ultrasound showed increased CD8+ T-cell infiltration and more perforin-positive cells.

Interpretation: The authors conclude that Bubble liposomes combined with ultrasound effectively deliver the IL-12 gene into tumor tissue, and that local IL-12 production induces an anti-tumor immune response. They propose this combination as a useful non-viral vector system for cancer gene therapy.

Limitations: Only one murine tumor model (OV-HM) was tested; therapeutic effect may depend on cancer type. - IL-12 concentration in tumor tissue was not directly measured; the authors estimate it may be in the tens of pg/mL range based on prior literature. - Single treatment did not achieve complete tumor regression. - No large-animal validation is reported. - Toxicity assessment was limited mainly to body weight and general observation.